Artrya(ASX) AYA

Market CapA$782.23M

Since IPO (2021)+215%

5 YearN/A

1 Year+253%

1 Month-17%

A$4.69

-2.29%

-0.11Today

Artrya last closing stock price
Metric	Price	Date
Last close	AUD 4.69	2026-08-13

Artrya stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+7.08%	AUD 4.38	2026-08-06
1 month	-17.43%	AUD 5.68	2026-07-14
3 month	-7.13%	AUD 5.05	2026-05-15
Year to date	-0.42%	AUD 4.71	2025-12-31
1 year	+252.63%	AUD 1.33	2025-08-13
3 year	+1,240%	AUD 0.35	2023-08-14
Since inception	+214.75%	AUD 1.53	2021-11-26

Artrya Financials at a Glance

Market Cap

A$782.23M

Revenue (TTM)

A$42.00K

Net Income (TTM)

-A$34.27M

EPS (TTM)

-A$0.17

P/E Ratio

-27.91

Dividend

A$0.00

Beta (Volatility)

-0.24 (Low)

Dividend

A$0.00

Beta (Volatility)

-0.24 (Low)

Price

A$4.69

Volume

765,219

Open

A$4.80

Price

A$4.69

Volume

765,219

Open

A$4.80

Previous Close

A$4.69

Daily Range

A$4.48 - A$4.81

52-Week Range

A$1.23 - A$6.49

Estimated Earnings Date

Aug 27, 2026

Dividend

A$0.00

Beta (Volatility)

-0.24 (Low)

Price

A$4.69

Volume

765,219

Open

A$4.80

Previous Close

A$4.69

Daily Range

A$4.48 - A$4.81

52-Week Range

A$1.23 - A$6.49

Estimated Earnings Date

Aug 27, 2026

AYA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Artrya

Artrya Limited is a medical technology firm specializing in artificial intelligence (AI) to identify individuals at risk of coronary artery disease. The company's flagship product, Salix, is a cloud-based software application that automates the analysis of coronary computed tomography angiography (CCTA) scans.

Products and Services

Salix: AI-driven software for coronary artery disease detection
Cloud-based platform for secure data management
Comprehensive analytics for healthcare providers

Growth Outlook

Significant market potential in the healthcare AI sector
Increasing demand for automated diagnostic solutions
Strategic partnerships to enhance product offerings and reach

Financial Highlights

Recent quarterly revenue of AUD 14,000, reflecting ongoing development
Cash and short-term investments totaling AUD 76.67 million
Current ratio of 37.11 indicates strong liquidity position

Artrya Limited is positioned in a rapidly growing sector, leveraging advanced AI technology to address critical healthcare challenges. The company's innovative approach to coronary artery disease detection through Salix offers significant advantages in efficiency and accuracy. With a robust cash position, Artrya is well-equipped to navigate the evolving landscape of medical technology. The focus on strategic partnerships and market expansion further enhances the potential for growth, making it an intriguing prospect for investors interested in the intersection of healthcare and technology.

AI Generated • Jul 30, 2026

Industry

Health Care Technology

Sector

Health Care

CEO

Mathew Regan

Website

www.artrya.com

Headquarters

West Perth, WA 6005, AU

AYA Financials

Key Financial Metrics (TTM)

Gross Margin

-43434.48%

Operating Margin

-75741.38%

Net Income Margin

-67958.62%

Return on Equity

-35.63%

Return on Capital

-75.84%

Return on Assets

-21.38%

Earnings Yield

-3.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$782.23M

Shares Outstanding

162.96M

Volume

765.22K

Avg. Volume

672.60K

Financials (TTM)

Gross Profit

-A$16.61M

Operating Income

-A$29.48M

EBITDA

-A$39.89M

Operating Cash Flow

-A$33.10M

Capital Expenditure

-A$369.00K

Free Cash Flow

-A$33.47M

Cash & ST Invst.

A$76.67M

Total Debt

A$546.00K

Artrya Performance Analysis

Artrya annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-06-30	AUD 0	N/A
2023	2023-06-30	AUD 0	N/A
2024	2024-06-30	AUD 0	N/A
2025	2025-06-30	AUD 28,000	N/A

Artrya sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-06-30	N/A
Q2	2024-12-31	N/A
Q4	2025-06-30	15.4%
Q2	2025-12-31	-6.7%

Artrya annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-06-30	AUD -0.26	N/A
2023	2023-06-30	AUD -0.14	-45.2%
2024	2024-06-30	AUD -0.18	25.3%
2025	2025-06-30	AUD -0.18	-0.2%

Artrya sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-06-30	99.8%
Q2	2024-12-31	-91100.0%
Q4	2025-06-30	4.6%
Q2	2025-12-31	1.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

A$14.00K

N/A

Gross Profit

-A$609.00K

+38.4%

Gross Margin

-43.50%

N/A

Market Cap

A$782.23M

N/A

Market Cap/Employee

A$18.19M

N/A

Employees

N/A

Net Income

-A$10.74M

-212.3%

EBITDA

-A$12.23M

-109.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

A$76.67M

+397.0%

Total Debt

A$546.00K

-49.4%

Accounts Receivable

A$9.22M

+357.9%

Inventory

A$0.00

N/A

Long Term Debt

A$186.00K

-76.5%

Short Term Debt

A$360.00K

-37.7%

Return on Assets

-21.38%

N/A

Return on Invested Capital

-24.44%

N/A

Free Cash Flow

-A$10.95M

-56.1%

Operating Cash Flow

-A$10.88M

-55.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IMR.AXImricor Medical Systems, Inc.

IMR.AXImricor Medical Systems, Inc.A$2.05+5.13%

CGS.AXCogstate Limited

CGS.AXCogstate LimitedA$2.74-0.36%

AVR.AXAnteris Technologies Ltd

AVR.AXAnteris Technologies LtdA$12.33-4.05%

PSQ.AXPacific Smiles Group Limited

PSQ.AXPacific Smiles Group LimitedA$2.18+0.00%

MYX.AXMayne Pharma Group Limited

MYX.AXMayne Pharma Group LimitedA$3.24-0.92%

OCC.AXOrthocell Limited

OCC.AXOrthocell LimitedA$0.79-0.63%

DXB.AXDimerix Limited

DXB.AXDimerix LimitedA$0.30+1.72%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$8.97-0.08%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.61+0.07%

SMCISuper Micro Computer

SMCISuper Micro Computer$39.42+0.05%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$144.56-0.01%

FGIFgi Industries

FGIFgi Industries$12.34+1.61%

NOKNokia

NOKNokia$10.56+0.02%

PATHUiPath

PATHUiPath$16.48+0.08%

Questions About AYA

What is the current price of Artrya?

Artrya is trading at A$4.69 per share.

What is the 52-week range for Artrya?

Over the past 52 weeks, Artrya has traded between A$1.23 and A$6.49.

How much debt does Artrya have?

As of the most recent reporting period, Artrya reported total debt of A$624.00K.

How much cash does Artrya have on hand?

Artrya reported A$11.48M in cash and cash equivalents in its most recent financial results.

What is Artrya’s dividend yield?

Artrya does not currently have a dividend yield.

Artrya(ASX) AYA

Artrya Financials at a Glance

AYA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Artrya

AYA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Artrya Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AYA

What is the current price of Artrya?

What is the 52-week range for Artrya?

How much debt does Artrya have?

How much cash does Artrya have on hand?

What is Artrya’s dividend yield?

Premium Investing Services